CGN — Cognetivity Neurosciences Share Price
0.000.00%
Last trade - 00:00- CA$1.79m
- CA$3.14m
- CA$0.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 2 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -4192.15% | ||
Financial Summary
| Year End 31st Jan | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | 0.05 | 1.02 | 6.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Company’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
Directors
- Last Annual
- January 31st, 2023
- Last Interim
- October 31st, 2023
- Incorporated
- December 11th, 2015
- Public Since
- March 19th, 2018
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 89,556,611
- Address
- Suite 1430, 800 West Pender St., VANCOUVER, V6C 2V6
- Web
- https://www.cognetivity.com/
- Phone
- +1 6043630411
- Auditors
- MNP LLP
Upcoming Events for CGN
Q2 2024 Cognetivity Neurosciences Ltd Earnings Release
Q3 2024 Cognetivity Neurosciences Ltd Earnings Release
Similar to CGN
Aquarius Surgical Technologies
Canadian Securities Exchange
Cannabix Technologies
Canadian Securities Exchange
Gemina Laboratories
Canadian Securities Exchange
Izotropic
Canadian Securities Exchange
Justera Health
Canadian Securities Exchange
FAQ
What is the Cognetivity Neurosciences share price?
As of Today at 19:05 UTC, shares in Cognetivity Neurosciences are trading at CA$0.02. This share price information is delayed by 15 minutes.
How has the Cognetivity Neurosciences share price performed this year?
Shares in Cognetivity Neurosciences last closed at CA$0.02 and the price had moved by -94.12% over the past 365 days. In terms of relative price strength the Cognetivity Neurosciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -94.42% over the past year.
What are the analyst and broker recommendations for Cognetivity Neurosciences?
The overall consensus recommendation for Cognetivity Neurosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cognetivity Neurosciences dividend yield?
Cognetivity Neurosciences does not currently pay a dividend.
Does Cognetivity Neurosciences pay a dividend?
Cognetivity Neurosciences does not currently pay a dividend.
When does Cognetivity Neurosciences next pay dividends?
Cognetivity Neurosciences does not currently pay a dividend.
How do I buy Cognetivity Neurosciences shares?
To buy shares in Cognetivity Neurosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cognetivity Neurosciences?
As of the previous close price of CA$0.02, shares in Cognetivity Neurosciences had a market capitalisation of CA$1.79m.
Where are Cognetivity Neurosciences shares listed?
Here are the trading details for Cognetivity Neurosciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: CGN
What kind of share is Cognetivity Neurosciences?
Based on an overall assessment of its quality, value and momentum Cognetivity Neurosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cognetivity Neurosciences share price forecast for 2024?
The analyst consensus target price for shares in Cognetivity Neurosciences is CA$0.75. That is 3650% above the last closing price of CA$0.02.
Analysts covering Cognetivity Neurosciences currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.07 for the next financial year.
What is the trend in the Cognetivity Neurosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cognetivity Neurosciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -84.12%.
As of the last closing price of CA$0.02, shares in Cognetivity Neurosciences were trading -84.26% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cognetivity Neurosciences PE Ratio?
The Cognetivity Neurosciences PE ratio based on its reported earnings over the past 12 months is 2. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cognetivity Neurosciences?
We do not have data on Cognetivity Neurosciences' directors